Market Place
Sourcing Support
CivicaScript® Lowers Price of its Generic Abiraterone Tablets
24 Feb 2025 //
PR NEWSWIRE
FDA Approves FoundationOne Liquid CDx As Companion Diagnostic For AKEEGA
01 Jul 2024 //
BUSINESSWIRE
ASCO: Lilly seeks prostate cancer redemption after Verzenio flop
23 May 2024 //
FIERCE PHARMA
Lilly’s growth drivers, Verzenio and Jardiance, suffer setbacks
01 May 2024 //
FIERCE PHARMA
AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360
03 Oct 2023 //
BUSINESSWIRE
LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan
24 Aug 2023 //
BUSINESSWIRE
FDA approves J&J`s PARP combo drug Akeega for prostate cancer
12 Aug 2023 //
FDA
Mylan`s Abiraterone Acetate Receives Approval in Europe
18 Jul 2023 //
EMA
Health Canada approves Lynparza with abiraterone for patients with BRCA mCRPC
14 Jul 2023 //
BIOSPACE
LYNPARZA® (olaparib) plus abiraterone approved in the US
01 Jun 2023 //
BUSINESSWIRE
FDA clears Lynparza combo for BRCA-mutated prostate cancer
01 Jun 2023 //
FDA
US FDA panel backs restricted use of AstraZeneca`s prostate cancer drug
02 May 2023 //
BUSINESS-STANDARD
FDA panel gives Lynparza narrow backing in prostate cancer
29 Apr 2023 //
FIERCE PHARMA
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib)
28 Apr 2023 //
BUSINESSWIRE
Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales
28 Apr 2023 //
ENDPTS
MHRA approves prostate cancer combination therapy
21 Mar 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Lynparza`s final OS results come up short in PROpel study
17 Feb 2023 //
PRESS RELEASE
Tavanta Announces Positive Top-line Results from Pivotal Phase 3 Trial
05 Jan 2023 //
PR NEWSWIRE
LYNPARZA With Abiraterone and Prednisone Approved in the EU for mCRPC
21 Dec 2022 //
PRESS RELEASE
LYNPARZA® in Combo With Abiraterone & Prednisone or Prednisolone Approved in EU
21 Dec 2022 //
BUSINESSWIRE
FDA delays review on AZ and Merck`s Lynparza in prostate cancer
16 Dec 2022 //
FIERCEPHARMA
AZ, MSD’s Lynparza in combo with abiraterone recommends for approval in EU
15 Nov 2022 //
PHARMABIZ
POINT Provides Updated Safety Data from PIII SPLASH Trial in mCRPC at ESMO 2022
09 Sep 2022 //
GLOBENEWSWIRE
Lynparza combo accepted by FDA for priority review
17 Aug 2022 //
THEPHARMALETTER
CivicaScript Announces Launch of its First Product
03 Aug 2022 //
BUSINESSWIRE
Improved outcome for prostate cancer patients in Phase III PROpel trial
22 Jun 2022 //
EUROPEANPHARMACEUTICALREVIEW
Results From PIII PROpel Trial of LYNPARZA Plus Abiraterone in 1L mcrPC
21 Jun 2022 //
BUSINESSWIRE
Janssen Submits MAA for Niraparib & Abiraterone Acetate Dual Action Tablet
28 Apr 2022 //
BUSINESSWIRE
AstraZeneca/Merck win over J&J in battle over prostate cancer franchises
15 Feb 2022 //
ENDPTS
LYNPARZA + Abiraterone Reduced Risk of Disease Progression or Death by 34%
14 Feb 2022 //
BUSINESSWIRE
Oncogen Pharma`s Generic Abiraterone Acetate Receives Approval in the U.S.
05 Jan 2022 //
FDA
Abiraterone halves mortality risk from prostate cancer, ICR study finds
24 Dec 2021 //
CLINICALTRIALSARENA
Abiraterone Acetate, Prednisolone to ADT Improves Metastasis-Free Survival:ESMO
21 Sep 2021 //
TARGETDONC
Exelixis Announces PIb Results from COSMIC-021 Trial in Metastatic CRPC
18 Sep 2021 //
BUSINESSWIRE
Epizyme Announces Data from TAZVERIK Clinical Programs to be Presented ESMO 2021
14 Sep 2021 //
BUSINESSWIRE
Mylan`s Abiraterone Mylan (abiraterone acetate) Receives Approval In Europe
26 Aug 2021 //
EMA
Reduced Fatigue Reported With Abiraterone+Prednisone Treatment
19 Jul 2021 //
FIRSTWORDPHARMA
Amneal Pharma launches Abiraterone Acetate Tablets post USFDA nod
11 Jan 2021 //
IN
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment
30 Oct 2020 //
ICR
OS Data With Olaparib Herald Practice-Changing Treatment Of met-Prostate Cancer
22 Sep 2020 //
ESMO
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
21 Sep 2020 //
FIERCE BIOTECH
Veru Announces Data of VERU-111 Phase 1b Study in Metastatic Prostate Cancer
18 Sep 2020 //
GLOBENEWSWIRE
NICE sticks to Zytiga rejection
26 Jun 2020 //
PHARMATIMES
Breakthrough discovery to transform prostate cancer treatment
22 Jun 2020 //
SCIENCEDAILY
Breakthrough discovery to transform prostate cancer treatment
22 Jun 2020 //
SCIENCEDAILY
Dr. Reddy`s Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market
19 Jun 2020 //
PRESS RELEASE
Kangpu to Present Two Posters at the 2020 (AACR) Annual Meeting
17 Jun 2020 //
PRNASIA
Dr Reddys Lab`s Generic Nicotine polacrilex Receives Approval in US
23 May 2020 //
FDA
AZ, Merck`s Lynparza gets an edge over Rubraca with prostate win
25 Apr 2020 //
FIERCE PHARMA
New Paragraph IV Certifications as of April 7, 2020
08 Apr 2020 //
FDA
WHO to accelerate research and innovation for new coronavirus
12 Feb 2020 //
BIOSPECTRUMASIA
Zytiga, Ajovy among latest SMC decisions
14 Jan 2020 //
PHARMA TIMES
NHS Scotland recommends Janssen`s Zytiga combo for newly diagnosed prostate
14 Jan 2020 //
PHARMAFILE
Zytiga, Ajovy among latest SMC decisions
13 Jan 2020 //
PHARMATIMES
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial
15 Nov 2019 //
PR NEWSWIRE
Granules India gets USFDA nod for allergy treatment drug
21 Oct 2019 //
ECONOMICTIMES
Glenmark Pharms` Generic Abiraterone Acetate Receives Approval in US
18 Oct 2019 //
FDA
Glenmark Pharma gets USFDA nod for prostate cancer treatment drug
17 Oct 2019 //
MONEYCONTROL
